In fact, researchers at Stanford are already collaborating on initial clinical trials of an antibody that blocks cancer cells from displaying one such
death -
evading signal — a molecule called CD47.
The authors conclude that their six hallmarks — sustained proliferative
signaling,
evading growth suppression, resisting cell
death, replicative immortality, induction of angiogenesis, and invasion / metastasis — continue to provide a useful conceptual framework for understanding the biology of cancer.